BIOTRONIK announces Europe-wide release of Passeo-18 Lux Peripheral Vascular Drug Releasing Balloon


Vascular Intervention/BIOLUX P-I study confirms clinical efficacy of innovative product to treat de novo and restenotic femoropopliteal lesions

Biotronik has announced the release of its Passeo-18 Lux Drug Releasing Balloon (DRB) in all countries accepting CE mark, following recent CE approval.

The Passeo-18 Lux DRB catheter has already shown clinical efficacy in the BIOLUX P-I study. data collected at six month and 12 month intervals, which demonstrated that patients treated with Passeo-18 Lux were less likely to require treatment again.

BIOLUX P-I is a randomised, controlled study investigating the safety and performance of Passeo-18 Lux (n=30) versus an uncoated Passeo-18 PTA catheter (n=30) in the treatment of lesions in the femoropopliteal segment of up to 200mm in length. The primary endpoint is late lumen loss in the Passeo-18 Lux arm versus the uncoated percutaneous transluminal angioplasty (PTA) catheter arm. Secondary endpoints include the Target Lesion Revascularisation (TLR) rate and the Rutherford classification. The study enrolled patients at six centres in Germany and Austria.

Six-month primary endpoint data, evaluated by an independent core lab, previously documented significantly-reduced angiographic late lumen loss (LLL) (p=0.038*) in the Passeo-18 Lux arm (LLL= 0.55 ± 0.73 mm) versus the uncoated PTA catheter (LLL= 1.07 ± 1.01 mm). Binary restenosis was also reduced (p=0.048*) in the Passeo-18 Lux arm versus the uncoated PTA catheter (11.5% vs. 34.6% respectively).

At 12 months, Kaplan-Meier estimates demonstrated a freedom from TLR rate of 84.6% for patients treated with Passeo-18 Lux versus 58.3% of patients treated with an uncoated PTA catheter (p=0.064). Furthermore, patients receiving treatment with Passeo-18 Lux demonstrated greater improvement in Rutherford classification compared to baseline (72%) versus those receiving treatment with PTA (65.2%).

"Passeo-18 Lux has demonstrated excellent clinical results and supports our growing confidence in DRBs", commented Professor Dierk Scheinert, chief clinical investigator of BIOLUX P-I and department head at the Cardiac Center at Park Hospital in Leipzig, Germany.

"It is very deliverable and easy to use compared with other technologies and treatment options for these demanding vessels."

Passeo-18 Lux is a novel combination device for treating de novo and restenotic femoropopliteal lesions. Its design is based on that of the proven Passeo-18 PTA catheter, which is coated with a matrix of anti-proliferative paclitaxel and a biocompatible excipient-enabling an optimal drug transfer to the target lesion tissue. An additional element, however, unique to Passeo-18 Lux, is the novel protective insertion aid to facilitate easier device introduction and handling.

"The release of Passeo-18 Lux is a significant advancement for both physicians and patients, as DRBs are emerging as a safe and durable therapy option for lower limb arterial disease," said Alain Aimonetti, vice president of sales and business development at BIOTRONIK’s vascular tntervention unit.

"Our significant investment in developing outstanding peripheral vascular devices, supported by clinical evidence, is translating into real clinical benefits."

You may also like